NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

HOTH

Hoth Therapeutics Inc

Jul 14 • 04:00PM ET

1.43

Dollar change -0.01
Percentage change -0.69	%

Healthcare • Biotechnology • USA • NASD

Peers: KPRX ARTL ENVB ACXP ITRM MIST CPRX NMRA TEVA VIR

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.15	Insider Own	0.49%	Shs Outstand	13.17M	Perf Week	21.19%
Market Cap	18.89M	Forward P/E	-	EPS next Y	-0.43	Insider Trans	0.00%	Shs Float	13.14M	Perf Month	8.33%
Enterprise Value	7.60M	PEG	-	EPS next Q	-0.11	Inst Own	2.30%	Short Float	4.53%	Perf Quarter	77.75%
Income	-9.62M	P/S	-	EPS this Y	65.87%	Inst Trans	24.87%	Short Ratio	0.51	Perf Half Y	-24.74%
Sales	0.00M	P/B	1.63	EPS next Y	0.48%	ROA	-92.33%	Short Interest	0.60M	Perf YTD	91.15%
Book/sh	0.88	P/C	1.67	EPS next 5Y	26.83%	ROE	-99.35%	52W High	3.80 -62.37%	Perf Year	55.96%
Cash/sh	0.86	P/FCF	-	EPS past 3/5Y	55.48% 27.96%	ROIC	-83.39%	52W Low	0.58 146.55%	Perf 3Y	-85.98%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	10.87% 8.68%	Perf 5Y	-97.75%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	43.30%	Oper. Margin	-	ATR (14)	0.12	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.08	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	61.94	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	15.08	EPS Q/Q	41.13%	SMA20	12.05%	Beta	0.65	Target Price	5.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	29.94%	Rel Volume	0.21	Prev Close	1.44
Employees	6	LT Debt/Eq	0.00	Earnings	May 28	SMA200	41.57%	Avg Volume	1.16M	Price	1.43
IPO	Feb 15, 2019	Option/Short	No / Yes	EPS/Sales Surpr.	2.33% -	Trades		Volume	246,364	Change	-0.69%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-19	Initiated	The Benchmark Company	Speculative Buy	$10

Jun-27-25 11:50AM	Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial (TipRanks)
Jun-25-25 10:40AM	Hoth Therapeutics says HT-001 met primary endpoint in CLEER-001 study (TipRanks) -7.03%
08:38AM	Silo Pharma Enters into Letter of Intent to Form Joint Venture with Hoth Therapeutics to Develop Obesity Treatment Targeting $16 Billion Global Market (GlobeNewswire)
08:27AM	Hoth Therapeutics (HOTH) and Silo Pharma (NASDAQ: SILO) today announced the formation of a 50/50 joint venture to develop a first-in-class GDNF-based therapy licensed from the U.S. Department of Veterans Affairs. The therapy targets obesity and fatty liver disease. (PR Newswire)
Jun-24-25 10:36AM	Hoth Therapeutics HT-001 Interim Results First-in-Class Topical Therapy Preserves Cancer Treatment While Resolving Dermatologic Side Effects (PR Newswire)
08:03AM	Loading…
Jun-23-25 08:03AM	Hoth Therapeutics to host KOL Event Spotlighting HT-001, Novel Therapy (PR Newswire)
Jun-18-25 01:34PM	Hoth Therapeutics Regains Nasdaq Compliance - Clears Key Listing Hurdle, Reaffirms Path Toward Growth (PR Newswire)
08:22AM	Hoth Therapeutics Reports Positive Preclinical Safety Data for Cancer Fighting HT-KIT -- Dose-Dependent Liver Activity with No Observed Toxicity Supports IND Pathway (PR Newswire)
Jun-16-25 08:00AM	Hoth Therapeutics to Attend 2025 BIO International Convention (PR Newswire)
Jun-12-25 09:17AM	Hoth Therapeutics Secures Japanese Patent for Breakthrough HT-KIT Platform Targeting Mast Cell Diseases (PR Newswire) +7.58%
Jun-11-25 08:28AM	Hoth Therapeutics Launches Expanded Access Initiative for HT-001, Offering Critical Relief to Cancer Patients Facing Severe Skin Toxicities (PR Newswire) +5.60%
Jun-05-25 08:12AM	Hoth Therapeutics to Spotlight HT-001 in Investor-Focused KOL Event Addressing Breakthrough Combating Cancer Treatment Skin Toxicities (PR Newswire) -20.92%
May-12-25 11:44AM	/C O R R E C T I O N -- Hoth Therapeutics, Inc./ (PR Newswire)
07:30AM	Hoth Therapeutics Reports Positive Preclinical Results for HT-KIT, a Precision Antisense Therapy Targeting Rare and Aggressive KIT-Driven Cancers (PR Newswire)
Apr-17-25 08:01AM	Hoth Therapeutics Announces Granted Japanese Patent for Novel RNA-Based Cancer Therapy Targeting KIT Gene - Expands Global IP in Precision Oncology Platform (PR Newswire)
10:52AM	Loading…
Apr-16-25 10:52AM	Hoth Therapeutics reports interim data from Phase IIa trial of HT-001 for pruritus (Clinical Trials Arena)
Apr-15-25 08:19AM	Hoth Therapeutics Announces Positive Initial Data in Phase 2a Clinical Trial (PR Newswire)
Apr-02-25 08:02AM	Hoth Therapeutics Collaborates with Washington University on NIH Grant Application Advancing Alzheimer's Program Using NK-1 Receptor Antagonist HT-ALZ (PR Newswire)
07:58AM	Hoth Therapeutics Announces Positive Pre Clinical Data HT-ALZ Shows Promising Breakthrough in Alzheimer's Disease Research Acute treatment with HT-ALZ led to a rapid (~15%) reduction in brain interstitial fluid Aß levels, within 20 hours (PR Newswire)
Mar-31-25 04:45PM	Hoth Therapeutics Receives USPTO Filing Receipt for HT-001 Formulation Patent Application, Expanding Existing Patent Coverage (PR Newswire)
Mar-26-25 08:02AM	Hoth Therapeutics Advances Cancer Fighting HT-KIT Program with New Patent Filing and Preclinical Study Initiation (PR Newswire)
Mar-19-25 08:11AM	Hoth Therapeutics announces positive results from study of HT-KIT (TipRanks)
Mar-18-25 08:06AM	Hoth Therapeutics Announces Positive Preclinical Results for HT-KIT in Aggressive Cancer Gastrointestinal Stromal Tumors (GIST). HT-KIT Triggered Significant Tumor Cell Death as Early as 24 Hours Post-treatment (PR Newswire) -9.40%
Mar-10-25 08:02AM	Hoth Therapeutics Announces Plans to Submit Expanded Access Application for HT-001 to Support Cancer Patients in Need (PR Newswire)
Mar-05-25 01:40PM	Hoth Therapeutics Announces Positive Results for HT-001 in Treating EGFR Inhibitor-Associated Papulopustular Eruptions Findings to be Presented at the American Academy of Dermatology 2025 Annual Meeting (PR Newswire) -8.06%
Mar-04-25 08:16AM	Hoth Therapeutics Announces Positive Findings on GDNF's Potential as a Game-Changer in Obesity Treatment and Reduced Fatty Liver Disease (PR Newswire) +42.53%
Feb-10-25 08:22AM	Hoth Therapeutics Partners with OnTargetx R&D to Advance Research for Cancer fighting HT-KIT Cancer Therapeutic (PR Newswire) -6.90%
Jan-24-25 08:29AM	Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements (PR Newswire) -7.48%
Jan-21-25 08:29AM	Hoth Therapeutics Expands Intellectual Property Portfolio with Acquisition of New Patent Applications (PR Newswire) -5.33%
Jan-17-25 08:29AM	Hoth Therapeutics to Attend Sequire Investor Summit January 21-23, 2025 (PR Newswire) -5.06%
01:27PM	Loading…
Jan-08-25 01:27PM	Hoth Therapeutics Responds to Market Rumors and Shareholder Inquiries (PR Newswire) -16.67%
Jan-07-25 02:10PM	Hoth Therapeutics Soars 215% on Breakthrough Cancer Treatment Success (GuruFocus.com) +178.18%
08:29AM	Hoth Therapeutics Achieves Breakthrough in Phase 2a Trial: HT-001 Delivers 100% Success in Combating Cancer Treatment Skin Toxicities (PR Newswire)
Dec-26-24 07:58AM	Hoth Therapeutics Enters Partnership with the Department of Veterans Affairs to Develop Obesity Treatment (PR Newswire)
Nov-22-24 12:25PM	MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000 (Barrons.com)
Nov-20-24 07:38AM	Hoth Therapeutics Board of Directors Approves Bitcoin as Treasury Reserve Asset (PR Newswire)
Oct-29-24 12:43PM	Hoth Therapeutics Announces Update on Cancer Therapeutic HT-KIT Results Suggesting the Treatment Effectively Inhibited Tumor Growth in Preclinical Treatment Study (PR Newswire) +10.84%
Oct-15-24 06:38AM	Hoth Therapeutics Awarded Key US Patent for Groundbreaking Alzheimer's Treatment and Prepares for Clinical Trials of HT-ALZ with Formulation Now Underway (PR Newswire) +8.11%
Sep-17-24 07:57AM	Hoth Therapeutics Announces Promising Preclinical Results for Alzheimer's Drug HT-ALZ (PR Newswire) +5.94%
Sep-05-24 10:32AM	Hoth Therapeutics Announces Expansion of Clinical Sites for HT-001 Phase 2a Trial (PR Newswire) +77.49%
08:03AM	Hoth Therapeutics Announces Positive Data from First-of-its-Kind Human Patient Treatment of EGFRI-Associated Skin Toxicities with HT-001 (PR Newswire)
Aug-16-24 06:33AM	Hoth and Aronnax partner for HT-KIT cancer therapy development (Pharmaceutical Technology) +14.10%
Aug-15-24 08:04AM	Hoth Therapeutics and Aronnax Inc. Enter Master Services Agreement For HT-KIT Cancer Therapeutic (PR Newswire)
Jul-24-24 06:30AM	Hoth Therapeutics Partners with LTS Therapy Systems to Accelerate Novel Alzheimer's Treatment (PR Newswire) +10.09%
Jul-16-24 08:31AM	Hoth Therapeutics Expands Clinical Trial for Cancer Patients (PR Newswire) +5.68%
Jun-27-24 06:52AM	HOTH Stock Earnings: Hoth Therapeutics Beats EPS for Q4 2023 (InvestorPlace)
Jun-11-24 07:40AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace)
Jun-10-24 08:11AM	Hoth Therapeutics Announces Joint Development Agreement with Wise Systems International SRL to Utilize Artificial Intelligence for Drug Discovery (PR Newswire) -8.26%
May-15-24 09:54AM	HOTH Stock Earnings: Hoth Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
May-01-24 08:00AM	Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024 (PR Newswire)
Mar-27-24 02:00PM	Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds (PR Newswire) -7.38%
08:27AM	Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment (PR Newswire)
Mar-20-24 05:38AM	Hoth Therapeutics (HOTH) Up on Upbeat Alzheimer's Drug Data (Zacks) +8.15%
Mar-19-24 08:21AM	Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ (PR Newswire) +17.39%
Feb-29-24 08:38AM	Hoth Therapeutics Retains Venable LLP to Expand Its Patent Portfolio (PR Newswire) -5.38%
Feb-26-24 08:11AM	Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic (PR Newswire)
Feb-13-24 11:45AM	Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024 (PR Newswire)
Jan-18-24 08:20AM	Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients (PR Newswire) +6.20%
Dec-27-23 08:21AM	Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami (PR Newswire) +19.26%
Dec-05-23 08:33AM	Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies (PR Newswire)
Nov-14-23 08:37AM	Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT (PR Newswire)
Nov-10-23 08:00AM	Hoth Therapeutics to Present at NobleCon's 19th Annual Emerging Growth Investor Conference, December 3-5, 2023 (PR Newswire)
Oct-05-23 10:03AM	Hoth Therapeutics Announces Merveille.ai Artificial intelligence Initiative for Drug Discovery (PR Newswire)
Oct-02-23 08:33AM	FDA Grants Hoth Therapeutics Pre-IND Meeting for HT-KIT, Treatment for Cancer Patients (PR Newswire)
Sep-15-23 02:38PM	Hoth Therapeutics Announces Closing of $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (PR Newswire)
Sep-13-23 01:43PM	Hoth Therapeutics Announces $2.89 Million Registered Direct Offering Priced At-The-Market under Nasdaq Rules (PR Newswire) -28.36%
08:16AM	Hoth Therapeutics Announces Positive Results Killing Cancer Cells in Both Gastrointestinal Stromal Tumors and Acute Myeloid Leukemia (PR Newswire)
Sep-11-23 10:04AM	Hoth Therapeutics Announces FDA Accepts Pre-Investigational New Drug (Pre-IND) Submission for HT-KIT, Treatment for Cancer Patients (PR Newswire) +10.16%
Sep-06-23 08:12AM	Hoth Therapeutics Announces Positive Final Results from 14-day Phase 1b Clinical Trial of BioLexa (PR Newswire) +5.53%
Aug-09-23 08:13AM	Hoth Therapeutics Announces Positive Preclinical End Point Results of HT-ALZ Treatment for Alzheimer's Disease (PR Newswire) +11.11%
Jul-25-23 08:12AM	Hoth Therapeutics Announces Major Milestone of First Patient Dosed in Phase 2a Clinical Trial (PR Newswire)
Jul-19-23 08:02AM	Hoth Therapeutics Receives Protocol Approval for HT-001 Cancer Therapeutic (PR Newswire)
Jun-14-23 08:12AM	Hoth Therapeutics Announces IRB Approval for FDA Cleared First-In-Human Clinical Trial of HT-001 at Second Clinical Site (PR Newswire) +7.69%
Jun-06-23 03:01PM	Hoth Therapeutics Stock Almost Doubles in Tuesday's Trading Session, Here's Why (Benzinga) +78.19%
08:02AM	Hoth Therapeutics Announces Positive Preclinical Results of HT-ALZ treatment for Alzheimer's Disease (PR Newswire)
May-12-23 08:38AM	Hoth Therapeutics and Algorithm Sciences Terminate Letter of Intent to Merge (PR Newswire)
Apr-26-23 04:21PM	From Alzheimer's to PAH: Hoth Therapeutics and Algorithm Sciences Combine to Pursue High Blood Pressure Solutions (Benzinga) -8.42% -5.75%
08:18AM	Hoth Therapeutics and Algorithm Sciences Execute Letter of Intent to Merge (PR Newswire)
Mar-08-23 09:09AM	Hoth Therapeutics Announces Collaboration with First Active Clinical Site for its Phase 2 Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy (PR Newswire)
Feb-16-23 08:35AM	Hoth Therapeutics Retains ShareIntel to Investigate Illegal Naked Shorting Activity (PR Newswire) +21.15%
Feb-08-23 10:42AM	Why Are Hoth Therapeutics Shares Moving Today? (Benzinga) -19.07%
08:43AM	Hoth Therapeutics Announces Increased Positive Results of its Alzheimer's Therapeutic HT-ALZ (PR Newswire)
Jan-25-23 08:27AM	Hoth Therapeutics Announces Selection of First 3 Clinical Sites for its Phase 2 Clinical Trial to Treat Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy (PR Newswire)
Jan-03-23 04:38PM	Hoth Therapeutics Announces Closing of $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire) -15.90%
Dec-29-22 08:00PM	Hoth Therapeutics Announces $10 Million Private Placement Priced At-the-Market Under Nasdaq Rules (PR Newswire) +143.64% -27.24%
09:08AM	FDA Signs Off Hoth Therapeutics' Trial Application For HT-001 For Skin Cancers (Benzinga)
08:45AM	Hoth Therapeutics Announces FDA Acceptance of IND Application for HT-001 for the Treatment of Cancer Disorders Associated with Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy (PR Newswire)
Dec-01-22 10:45AM	Hoth Therapeutics Announces Submission of Investigational New Drug Application for HT-001 (PR Newswire)
Nov-09-22 12:38PM	Hoth Therapeutics Regains Compliance with Nasdaq Listing Requirements (PR Newswire) -6.71%
Oct-31-22 11:39AM	Hoth Therapeutics' Atopic Dermatitis Candidate Shows Improvement In Severity, Shares Jump (Benzinga)
09:57AM	HOTH THERAPEUTICS REPORTS POSITIVE BIOLEXA PHASE 1B CLINICAL TRIAL RESULTS IN MILD TO MODERATE ATOPIC DERMATITIS (PR Newswire)
Oct-24-22 04:15PM	Hoth Therapeutics Announces a 1:25 Reverse Stock Split Effective Pre-Market Opening on October 26, 2022 (PR Newswire) -26.37%
Sep-20-22 09:05AM	Hoth Therapeutics Announces Partnership with Altasciences for Manufacturing HT-TBI for Traumatic Brain Injury and Stroke (PR Newswire)
Sep-06-22 08:21AM	Hoth Therapeutics mRNA Frame-Shifting Therapeutic, HT-004, Shows Potential to Reduce Lung Inflammation in Asthma and Allergy Disorders (PR Newswire)
Aug-16-22 03:00PM	Sidoti's August Micro-Cap Virtual Conference (ACCESSWIRE)
Aug-12-22 01:48PM	Hoth Therapeutics Announces Pipeline Presentation at the 2022 Sidoti Investor Conference (PR Newswire)
Jul-12-22 02:24PM	Hoth Therapeutics Shares Surge On Encouraging Preclinical Data From Alzheimer's Program (Benzinga)
10:26AM	Hoth Therapeutics Announces HT-ALZ Therapeutic Shows Cognitive Improvements in Alzheimer's Disease Mouse Model (PR Newswire)
Jun-29-22 01:25PM	Hoth Therapeutics Granted 180 Day Extension by Nasdaq to Regain Compliance with Bid Price Rule (PR Newswire)
Jun-21-22 12:30PM	Hoth Therapeutics Announces HREC Approval in Australia for the Next Phase of its Trial of BioLexa for Patients with Atopic Dermatitis (PR Newswire)

Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Knie Robb	CEO and President	Aug 16 '24	Buy	0.67	25,000	16,750	58,131	Aug 19 08:00 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

HOTH

Hoth Therapeutics Inc

Upgrade your FINVIZ experience